Vector Space Biosciences, Inc., in collaboration with Oracle and NVIDIA, has announced the availability of its new small satellite (CubeSat) launch platform for biotechnology and pharmaceutical companies. The platform consists of a biosciences lab, a CubeSat lab, and a language modeling/AI lab. This pipeline allows for the development of countermeasures against diseases related to stressors from human spaceflight, which can also be used as precision medicine for all individuals.
Once a CubeSat is designed, developed, and launched, the data is transmitted to ground stations in collaboration with Microsoft Azure Space. The data is then augmented with current biomedical data and preprocessed for language modeling. Hidden relationship networks are constructed between genes, proteins, diseases, drug compounds, and other biochemicals using feature vectors extracted from trained models.
The data generated from CubeSats in space is valuable and powerful, offering the potential for new discoveries in drug discovery, development, design, and repurposing. For example, Novo Nordisk’s weight loss drug, Wegovy (semaglutide), has been shown to help patients lose an average of 15% of their weight and reduce the incidence of heart attack, stroke, or death from heart disease by 20%.
The founder and CEO of Vector Space Biosciences, Kasian Franks, emphasizes the importance of understanding how to protect and repair the human body during spaceflight. By focusing on creating solutions in this area, new therapeutic applications in precision medicine can be developed and repurposed for the benefit of all individuals.
Vector Space Biosciences trades under the cryptocurrency symbol SBIO and enables payments through its subsidiary, Vectorspace AI, and its utility token, VXV.
Vector Space Biosciences, Inc., along with its scientific collaborators, designs, develops, and launches biological small satellites (CubeSats) to generate and interpret unique datasets related to microgravity and radiation. These datasets contribute to the development of countermeasures against diseases associated with stressors during spaceflight, as well as advancements in space biosciences, biotechnology, and pharmaceutical development.
The company aims to accelerate the process of new hypothesis generation and novel discoveries in space biosciences by working with leading scientific labs in areas such as human aging, cancer, and nutrigenomics. Their platform is capable of producing over 100 billion different real-time datasets, leading to innovations in precision medicine and products and services for various industries.
For more information, please visit vectorspacebio.science.